Indication name: Achondroplasia
Achondroplasia – Market outlook,
Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
(Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan
& China).
Achondroplasia is the most common of the
skeletal dysplasias that result in marked short stature (dwarfism).
Achondroplasia is caused by mutations in the FGFR3 gene. This gene provides
instructions for making a protein that is involved in the development and
maintenance of bone and brain tissue. Two specific mutations in the FGFR3 gene
are responsible for almost all cases of achondroplasia.
Epidemiology- The condition occurs in 1 in
15,000 to 40,000 newborns worldwide. It is estimated about 1 case in 10,000
births in Latin America.
Competitive landscape of Achondroplasia includes country
specific approved as well as pipeline therapies. Any asset/ product specific
designation or review and Accelerated Approval are being tracked and
supplemented with analyst commentary.
KOLs insights of Achondroplasia across 8 MM
market from center of Excellence/ Public/ Private hospitals participated in the
study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
Achondroplasia Market Forecast: Patient
Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs
with sourcing, Market Event and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Stage
1 TransCon
CNP Ascendis Pharma A/S Phase 2
2 BMN
111 BioMarin Pharmaceutical Phase 2
3 Recifercept Pfizer Phase
2
4 Infigratinib QED Therapeutics, Inc. Phase 2"
No comments:
Post a Comment